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ABSTRACT 
Clopidogrel, an antithrombotic drug, has been proven by FDA as Plavix® was initially used 
for the prevention of vascular occlusive that cause of myocardial infarction, stroke, and vascular 
death in patients with atherosclerosis and then it is used to treat Acute Coronary Syndrome 
(ACS). Aim of the study is to compare the effectiveness of Clopidogrel to aspirin and ticlopidine 
by meta-analysis of CLASSICS (The Clopidogrel Aspirin Stent International Cooperative Study), 
MATCH trial dan CAPRIE trial. Results of the study show that the effectiveness of Clopidogrel is 
significantly higher, however the risk of ischemic and bleeding is lower than aspirin and 
ticlopidine. Cost-effectiveness of Clopidogrel in avoiding secondary stroke in one episode is 
approximately US $ 33,000, and aspirin is only US $ 1400.  In Indonesia the price of Clopidogrel  
is ranged from US $1.5 to US $3 each tablet, while the price of aspirin ranged from US $ 0.35  to 
US $ 0.72. However, in Indonesia Clopidogrel is now in the list of National Formulary, this fact 
might have contributed to the increasing use of Clopidogrel, which has reached around 1000 
tablets per day in each hospital while aspirin has reached  almost 1500 tablets per day.  
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ABSTRAK 
Clopidogrel sudah mendapat ijin edar dari FDA sejak November 1998 dengan nama  Plafiks@ dan 
digunakan untuk pencegahan vascular oclusive yang dapat menimbulkan myocard infarction dan stroke. 
Selanjutnya, Clopidogrel diindikasikan untuk pengatasan Acute Coronary Syndrom (ACS). Studi ini 
ditujukan untuk membandingkan efektifitas Clopidogrel dengan ticlopidine dan aspirin sebagai 
antithrombotik melalui meta-analisis, yaitu CLASSICS (The Clopidogrel Aspirin Stent International 
Cooperative Study), MATCH trial dan CAPRIE trial. Hasil studi menunjukkan bahwa Clopidogrel lebih 
efektif secara signifikan dibandingkan dengan  aspirin (5,32% vs 5,87%), dan risiko terjadinya serangan 
Ischemia dan perdarahan lebih rendah dibandingkan dengan aspirin dan ticlopidine. Biaya pencegahan 
terjadinya serangan stroke yang ke-dua dengan menggunakan Clopidogrel diperkirakan mencapai US $ 
33,000, sedangkan pada penggunaan  aspirin hanya sekitar US $ 1400. Sementara di Indonesia harga 
Clopidogrel  berkisar mulai dari US $ 1.5 sampai US $ 3 per tablet, 2 kali lipat harga aspirin yang hanya 
berkisar antara US $ 0.35 sampai US $ 0, 72. Namun demikian di Indonesia Clopidogrel saat ini juga 
sudah dimasukkan ke dalam Fornas. Kemungkinan hal inilah yang menyebabkan penggunaan Clopidogrel 
di Indonesia mulai meningkat, dengan penggunaan rata-rata per Rumah Sakit mencapai 1000 tablet per 
hari, dan aspirin lebih dari 1500 tablet per hari. 
 
Kata kunci:  antitrombotik, aspirin, antiplatelet, Clopidogrel, ticlopidine 
Jurnal Farmasi Sains dan Komunitas, 2017, 14(1), 65-73 
66  Titien Siwi Hartayu and Dewi Setyaningsih 
INTRODUCTION 
Clopidogrel, an antithrombotic drug, was 
approved by FDA to the market since November 
17, 1998. First approved by FDA, Clopidogrel 
known as Plavix® was initially used merely for the 
secondary prevention of vascular occlusive events 
that renders to the event of myocardial infarction, 
stroke, and vascular death in patients with 
atherosclerosis documented by recent stroke, 
recent myocardial infarction, or established 
peripheral arterial disease. In August 2001, 
Clopidogrel was used in unstable angina to prevent 
recurrent events for preventing of re-current 
vascular occlusive problem, and then in September 
2002, Clopidogrel has gained new indication for 
non-ST-segment elevation Acute Coronary 
Syndrome (ACS) (NHS, 2004).  
ACS is a set of signs and symptoms 
suggestive of sudden cardiac ischemia, usually 
caused by such event of eroded and ruptured 
atherosclerotic plaque as the results of sequential 
events involving platelet adhesion, activation and 
subsequent aggregation that can lead to vascular 
occlusion in an epicardial coronary artery. This 
evidence is also called as arterial thrombosis. The 
acute coronary syndromes include Unstable 
Angina (UA), Non-ST Segment Elevation 
Myocardial Infarction (NSTEMI), and ST 
Segment Elevation Myocardial Infarction 
(STEMI), commonly referred to as a heart attack. 
(Yeghiazarians, Braunstein, Askari, & Stone, 
2000) 
The patophysiology of ACS relies on the 
role of platelet activation. Normally, platelets do 
not interact with the endothelium of healthy 
vessels; however, as a result of inflammation 
cascades, platelets adhere to exposed 
subendothelial structure in damaged vessels. This 
action subsequently triggers a cycle of recruitment 
and adhesion of additional platelets and results in 
the expression and assembly of receptor for 
fibrinogen on the platelet surface. This receptor, 
the platelet glycoprotein (GP) IIb/IIIa receptor is 
the final common pathway for platelet aggregation 
as it binds to bivalent fibrinogen molecules to form 
platelet aggregates. Stable platelet aggregation is 
augmented by two autocrine factors genereated 
upon platelet stimulation: Adenosine diphosphate 
(ADP), release from platelet dense bodies, and 
TXA2 generated by sequential action of Cox-1 and 
thromboxane synthase on the arachidonic acid 
released from membrane phospholipids  (Philips, 
Conley, Sinha, & Andre, 2005; Sharis, Cannon, & 
Loscalzo, 1998; Weitz & Hirsh, 1998).  
Clopidogrel, a member of thienopyridines, 
is an antiplatelet agent by first aid of cytochrom 
P450 (CYP) activation, and accordingly its active 
metabolite drug acts as a selective inhibitor for 
adenosine diphosphate (ADP)-induced platelet 
aggregation and thereby affecting ADP-dependent 
activation of the glycoprotein GPIIb/IIIa complex 
(Figure 1), the major receptor for fibrinogen 
present on the platelet surface. Therefore, platelet 
aggregation can be prevented. Aspirin, another 
antithrombotic agent, acts in different way with 
Clopidogrel or ticlopidine as aspirin prevent 
thrombotic event via blocking thromboxane A2-
dependent platelet recruitment (Weitz and Hirsh, 
1998). Combination of Clopidogrel and aspirin 
showed synergistic effect in studies using models 
of thrombosis (Harker et al., 1998; Herbert et al., 
1998). 
 
 
 
Figure 1. Selective blockage platelet activation by Clopidogrel, aspirin and GPIIb/IIIa 
antagonists (Weitz & Hirsh, 1998) 
 
Jurnal Farmasi Sains dan Komunitas, 2017, 14(1), 65-73 
 
The Effectiveness of Clopidogrel …  67 
THE RATIONAL PATHWAY OF DRUG 
DISCOVERY APPLIES ON THE 
DEVELOPMENT OF CLOPIDOGREL  
Based on the understanding of the 
patophysiological pathway of 
atherothrombosis event and antagonism 
activity on preventing thrombotic event, 
Clopidogrel, was developed by chemical 
modifying of previously found drug 
ticlopidine, an antagonist of ADP receptor 
(Bhatt, Bertrand, Berger, 2002; Sado, 2001). 
Moreover, since ticlopidine, the drug that exist 
before shows remarkable side effect of 
causing neutropenia, Clopidogrel was 
discovered for the aim of a better drug effect 
with lower toxicity.  
There were found abundant information 
about the effectiveness and safety of 
Clopidogrel over the previous found drug 
ticlopidine. In animal study, modelled for 
thrombosis, Clopidogrel showed its higher 
activity compared to ticlopidine (Herbert, 
Tissinier, Defreyn, Maffrand, 1993). 
Compared with the preceding antihrombotic 
agent, ticlopidine, the safety and tolerability of 
Clopidogrel showed superior to ticlopidine in 
CLASSICS (The Clopidogrel Aspirin Stent 
International Cooperative Study) (Bertrand, 
Rupprecht, Urban, Gershlick, 2000).Based on 
these abundant research in safety and 
effectiveness of Clopidogrel, Sanofi-Syntelabo 
applied for its approval to FDA.    
 
EFFECTIVENESS AND SAFETY 
STUDIES AND META-ANALYSIS 
The efficacy of Clopidogrel was 
weighed by evaluating its effect on reducing 
the composite primary endpoint of 
atherethrombotic event from Clopidogrel 
compared to aspirin in CAPRIE studies 
(Committee, 1996). This randomized, blinded 
study, involved 19,185 patients with a high 
risk of atherothrombotic event, from 384 
centres in 16 different countries. These 
patients were assigned in 3 years study and 
divided into two group, one group was treated 
with 75 mg daily of Clopidogrel while another 
one were 325 mg of aspirin.  The outcome was 
set on composite endpoints, which are 
vascular death, myocardial infarction (MI), 
and or ischaemic stroke. Effectiveness of 
Clopidogrel is slightly but significantly higher 
than aspirin as proven in this report that 
treatment with Clopidogrel showed the 
primary endpoint 5.32% vs 5.87% with 
aspirin. This report also suggested the overall 
risk reduction of 8.7% (95% CI 0.3, 16.5; 
P=0.043) by Clopidogrel. The effectiveness of 
Clopidogrel was also confirmed by reducing 
the total number of hospitalizations for 
ischemic events and bleeding in Clopidogrel 
compared with aspirin over an average of 1.6 
years of treatment.  
Despite the slightly higher in the 
effectiveness of Clopidogrel compared to 
aspirin in CAPRIE study targeted for patient 
suffered from high risk of atherothrombotic 
event, there were reported evidence that the 
more significant benefit of Clopidogrel is 
favorable seen in patients enrolled in CAPRIE 
with pre-existing symptomatic 
atherothrombotic disease or additional risk 
factors such as diabetes mellitus and 
hypercholesterolaemia. In these sub-groups of 
CAPRIE trial, 4,496 patients had previously 
suffered an ischaemic stroke and MI, and were 
a substantially elevated risk of 
atherothrombotic events, resulted in primary 
endpoint of 8.8% in Clopidogrel group 
compared to 10.2 % in the aspirin treated 
group (Ringleb, Bhatt, Hirsch, 2004). 
Moreover, the beneficial effect of Clopidogrel 
was amplified by the result of a relative risk 
reduction of Clopidogrel over aspirin of 14.9% 
(95% CI 0.3, 27.3; P = 0.045) and absolute 
risk reduction of 3.4% (34 events avoided per 
1000 patients per year among the 19,825 
patients enrolled CAPRIE per 2 years 
(Durand-Zaleski and Bertrand, 2004).  
The beneficial effect of Clopidogrel was 
also observed from CAPRIE study assigned 
for the group with diabetic pre-existing 
disease. The annual event rate for the 
composite endpoint of vascular death, MI, 
stroke or re-hospitalization for ischaemia or 
bleeding was 15.6% in the Clopidogrel group 
and 17.7% in the aspirin group. The advantage 
of Clopidogrel treatment versus aspirin 
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confirmed by the report of relative risk 
reduction of 13.1% favorable to Clopidogrel 
(95% CI 1.2, 23.7; P = 0.032). Moreover, the 
absolute risk reduction in patient with diabetic 
history was 21% for Clopidogrel versus 11% 
for aspirin therapy (Bhatt, Marso, Hirsch, 
2002).    
In the safety study in CAPRIE, there 
was evidence that Clopidogrel was also 
associated with lower risk of bleeding 
complications compared with aspirin as 
demonstrated by lower gastrointestinal 
haemorrhage (1.99 vs 2.66% P < 0.05) and 
trend towards a lower incidence of intracranial 
haemorrhage (0.33 vs 0.47% P = 0.23) 
(Committee, 1996). Furthermore the safety of 
clopidogrel was reported superior than the 
precedence antiplatelet agent ticlopidine. 
Clopidogrel did not cause the severe 
hematologic side effect compared to 
ticlopidine (Steinhubl, Tan, Foody, Topol, 
1999). Additionally, Clopidogrel is better 
tolerated than aspirin, since the onset of action 
is more rapid and the once-a-day dosing 
regiment is more convenient (Bhatt, Bertrand, 
Berger, 2002).   
Comparison in safety and efficacy study 
also assigned for Clopidogrel and ticlopidine 
in meta analysis of randomized and registry of 
ticlopidine with Clopidogrel after stenting 
(Bhatt, Bertrand, Berger, 2002). The research 
which involved almost 14,000 patients showed 
the efficacy of Clopidogrel is superior to 
ticlopidine. The author suggested that this is 
due to better patient compliance to 
Clopidogrel as demonstrated in the 
randomized CLASSIC data (Bertrand, 
Rupprecht, Urban, Gershlick, 2000). From the 
hematologic profile of Clopidogrel compared 
to ticlopidine, it was fortified that possibility 
of long-term therapy with Clopidogrel is more 
acceptable than long-term ticlopidine therapy 
(Bhatt, Bertrand, Berger, 2002).   
Combination of Clopidogrel and low 
dose of aspirin is recently being the favorable 
standard antiplatelet therapy, replacing the 
dual combination aspirin and ticlopidine. This 
new strategy is supported by a large amount 
pre-clinical and clinical research on the 
efficacy and safety of Clopidogrel over 
ticlopidine. A pre-clinical study showed that 
co-therapy of aspirin with Clopidogrel set with 
loading dose and daily dose, reduce 
significantly graft and stent thrombosis event. 
Synergisms between aspirin and Clopidogrel 
was also demonstrated by Makkar et al in ex 
vivo study (Makkar et al., 1998). Clinical 
study fase III in CURE study confirmed the 
benefit of dual combination Clopidogrel and 
Aspirin. In this study that involved 12,562 
patients with acute coronary syndrome without 
ST-segment elevation, combination Plavix 
(Clopidogrel)-aspirin showed the reduction in 
the number of patient experiencing the 
primary endpoint (CV death, MI, or stroke). In 
the plavix treated group 9.3% patients 
experienced the primary endpoint compared to 
11.41% in those plavix untreated group. 
Moreover, at the end of 12 months, the co-
primary outcome (CV, MI, stroke or refractory 
ischemia was 16.54% in the plavix-treated 
group and 18.83% in aspirin treated group. 
 
NEW INDICATION FOR 
CLOPIDOGREL 
Previously, Clopidogrel was indicated 
for the reduction of atheroschlerotic events 
including myocardial infarction, stroke, or 
peripheral artery disease, and is used in 
patients with non–ST segment elevation acute 
coronary syndrome for those who are going to 
be medically managed or to receive 
percutaneous coronary intervention 
(Aschenbrenner and Price, 2007).   
New  indication of Clopidogrel appears 
as the results from the trial of Unstable angina 
to prevent Recurrent Event (CURE) led to 
FDA approval to the new indication that 
includes indication for the prevention of 
thrombotic events in patients who had 
myocardial infarction with acute ST-segment 
elevation and are not going to have coronary 
artery stenting (Aschenbrenner and Price, 
2007). According to this setting, a loading 
dose of 300 mg followed by 75 mg daily 
should be used. 
 
IMPACT OF DRUG IN THERAPY 
In the therapy of using antiplatelet drug 
administered orally, aspirin is the first-line 
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antiplatelet therapy for patients with ST-
segment elevation myocardial infarction (MI) 
(Diener, 2002; Donnan and Davis, 2002; Tran 
and Anand, 2004; Warlow, 2002). This is 
because from the calculation of cost-
effectiveness there no other antiplatelet drug is 
superior compared to aspirin. From the data 
presented by Garattini S and Bertele V, 
monthly cost for secondary prevention of 
cardiocasvular event, the cost is €2.3; €14.0; 
€70.0 for aspirin, ticlopidine, and Clopidogrel 
respectively (Garattini and Bertele, 2004). For 
the patients who are showing their intolerance 
with aspirin, then Clopidogrel is given in the 
substitution of aspirin. In the second line of 
therapy is the combination of aspirin plus 
Clopidogrel for patients with recurrent acute 
coronary syndrome. However, in the MATCH 
trial, a trial to study the combination therapy 
of aspirin and Clopidogrel in term of the 
safety and efficacy in the patient with stroke 
disease, showed that the combination therapy 
of aspirin and Clopidogrel non-significantly 
reduces the relative risk of the primary 
endpoint which are myocardial infarction, 
ischemic stroke, and vascular death. 
Moreover, in the safety point, there was 
significantly increased in life-threatening 
bleeding for the combination therapy of 
Clopidogrel and aspirin (Amarenco and 
Donnan, 2004).   
The use of Clopidogrel in patient suffer 
from ACS disease is in the alternative agent as 
the first treatment the doctors are still choose 
for aspirin. Only for the patient who has 
gastrointestinal intolerance to aspirin and with 
an allergy to aspirin, Clopidogrel is the drug of 
choice in the treatment of ACS (Braunwald, 
Antman, Beasly, 2002). 
 
HEAD TO HEAD COMPARISON 
A large trial carried in CAPRIE clinical 
studies provides the head to head comparison 
between Clopidgrel and aspirin in the 
prevention of recurrent of ischemic events in 
patients at high risk of ischemia events (acute 
myocardial infarction (AMI), stroke, 
symptomatic peripheral arterial disease). The 
primary end point was the combination in 
prevention of MI, ischemic stroke, or vascular 
death. Clopidogrel significantly reduced the 
relative risk of the primary endpoint by 8.7% 
(Commitee, 1996). Contrary to the result of 
superiority Clopidogrel over aspirin, 
significant benefit of Clopidogrel is no longer 
established when statistical calculation is 
made in separated index event. In preventing 
the recurrent  of AMI, and stroke, the 
advantage of Clopidogrel is much smaller and 
is not significantly different with aspirin 
treatment group. The greater significant 
benefit of Clopidogrel is obtained in the group 
with peripheral arterial disease.  Therefore, the 
significant benefit of Clopidogrel is driven by 
peripheral arterial disease group (Gebel, 2005; 
Hankey, 2005).  
Comparative study between Clopidogrel 
and aspirin is thought to be less rational since 
the aim of developing Clopidogrel was to 
discover a better and less toxic drug than 
ticlopidine. Although a meta-analysis study in 
comparison of Clopidogrel and ticlopidine 
after stenting was available    (D. L. Bhatt, 
Bertrand, Berger, 2002), it gain critics that the 
study was performed in too short time for 
observation of primary endpoint (30 days) 
(Garattini and Bertele, 2004).  
Another randomized comparison study 
of Clopidogrel and triclopidin in their 
combination with aspirin for 28 months 
showed that a higher mortality was found in 
the Clopidogrel group instead of triclopidie 
(Mueller et al., 2003). However in CAPRIE 
trial, neutropenia as observed in ticlopidine 
side effect, was less in Clopidogrel and aspirin 
(0,10% for Clopidogrel and 0.17% in aspirin) 
(Commitee, 1996).  
 
REIMBURSEMENT 
Effectiveness studies on comparison of 
Clopidogrel and the standard therapy, aspirin 
in CAPRIE trial showed that although 
Clopidogrel significantly attenuated platelet 
induced aggregation, however, the beneficial 
effect of Clopidogrel over aspirin is 
considerably modest. Therefore additional 
benefit is likely statistically and the drug has 
not been granted a claim of superiority over 
aspirin by the regulatory authorities. In the 
CAPRIE trial which compared Clopidogrel 
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versus aspirin, there was a significantly 
reducing for stroke, MI or vascular death in 
favour of Clopidogrel (in approximately 8% p 
= 0.03). However, one publication reported 
that the CAPRIE trial was not powered to 
detect treatment differences within patient 
subgroups. Moreover, based on the statistical 
analyses, it was revealed a significant patient 
heterogeneity with respect to the results for the 
various subgroups in CAPRIE trial (p=0.042). 
When patients from the stroke and peripheral 
arterial disease (PAD) were pooled out, the 
results favored Clopidogrel. However, it is 
noticed that the proportion of patient with 
PAD is much bigger than that of stroke. 
Therefore the conclusion in comparison of 
Clopidogrel and aspirin in secondary 
prevention of cardiovascular disease was 
driven by disproportionality of group with 
PAD reflects the conclusion. Apparently when 
the results for subgroups were compared, there 
was no significant difference between 
Clopidogrel and ASA in patients with stroke 
or MI (Gebel, 2005). 
Three years after the approval of 
Clopidogrel by FDA, the Netherlands 
government decided to put Clopidogrel in the 
list of drug reimbursement. Regulation of 
reimbursement of Clopidogrel in Netherlands 
was released in 26 of July 2000 (Algra and 
Gijn, 2000). The official indication for 
Clopidogrel is secondary prevention in 
patients with atherosclerotic disease and 
proven to be aspirin sensitive. However, even 
though many publication recommend the use 
of Clopidogrel in one-year treatment to reduce 
ACS, Netherlands government allowed for its 
reimbursement only for 6-months therapy with 
Clopidogrel. There are three principle criteria 
in establishing a decision for reimbursement 
of drug, i.e., therapeutic benefit, cost-
effectiveness evidence, and burden of disease.  
This strict reimbursement policy of 
allowing only 6-month therapy with 
Clopidogrel is supported by the study on the 
calculation of cost-effectiveness in stroke 
management on Clopidogrel. A study by 
Niessen et. al. revealed that using 
acetylsalycilic acid was more cost-effective 
compared to Clopidogrel (Niessen, Dippel, 
Limburg, 2000). The cost value in cost-
effectiveness study made for comparison of 
Clopidogrel and aspirin revealed that the cost 
for avoiding one stroke episode in secondary 
stroke prevention is approximately US$ 
33,000 with Clopidogrel, whereas calculated 
cost with aspirin is only US$ 1,400 (Algra and 
Gijn, 2000).   
Relative to the cost of using Clopidogrel 
and aspirin, an observation revealed that the 
price of Clopidogrel in Indonesia ranged from 
US $1.5 to $3 each tablet, higher than aspirin 
(ranged from 3.50 cent to 7.2 cent) of course, 
the cost of using Clopidogrel is higher and 
almost twice compared to aspirin. However, 
Clopidogrel is now included in the drug list 
which covered by government insurance 
(BPJS), so it will not too burden on the 
patients’ own financial and this fact might 
have contributed to the increasing use of 
Clopidogrel in Indonesia. In Indonesia 
Clopidogrel usage as an antithrombotic in 
each hospital has reached 1000 tablets per day, 
however aspirin is still higher than 
Clopidogrel, it has reached almost 1500 tablets 
per day. 
 
CONCLUSION 
Clopidogrel can be chosen in caring for 
cardiovascular disease especially in reducing 
the incidence of stroke, MI, or vascular 
disease. 
 
ANNEX 
1. How was the Clopidogrel discovered? 
Clopidogrel discovery is clearly not by 
chance, and was discovered through 
rational pathway of research since there is 
understanding pathological pathway of 
acute cardiovascular disease (ACD). 
Clopidogrel is antiplatelet drug belongs to 
the class of thienopyridine. Ticlopidine is 
also a thyenopiriden member, but because 
of considerable side effect (neutropenia), 
Clopidogrel was developed with the aim of 
having a better effect with the lower drug 
toxicity. The chemical structure of 
Clopidogrel and ticlopidine is analogous. 
2. What was the route of leading registration 
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Prior to registration the drug had been 
assigned for a big clinical trial (CAPRIE) 
involving 19185 patients from 384 centres 
in 16 different countries in the world. 
Therefore the big phase III clinical study 
have been performed. 
3. Are meta-analysis available? 
Yes. Meta-analysis is available in the 
CAPRIE study and in the comparison of 
effectiveness study between Clopidogrel 
and ticlopidine.  
4. Were studies on hard endpoints available? 
Yes. The hard endpoint in Clopidogrel 
compared to aspirin is the composite 
endpoint of myocardial infarction, ischemic 
stroke and vascular death. This hard 
endpoint is the parameter measured in 
CAPRIE trial.  
5. Were head to head comparison trial 
performed? 
The data in head to head comparison is 
available in the comparison of Clopidogrel 
to aspirin in the CAPRIE trial. However, 
there is scarce information in the 
comparison of Clopidogrel to ticlopidine. 
The available data of comparion of 
Clopidogrel and ticlopidine is available 
through the meta-analysis study (Bhatt, 
Bertrand, Berger, 2002) involving 13, 955 
patients. However by other author this 
comparison was criticized for the only 30 
days of observation in the measurement of 
the hard endpoint (mortality)(Garattini and 
Bertele, 2004). 
6. What happened after the drug on the 
market? Is it reimbursed? 
Yes. Drug reimbursement by the Dutch 
government is already in 26 July 2000. The 
reimbursement for Clopidogrel is applied 
for 6 months therapy. This limited time and 
strict regulation in Dutch government for 
the reimbursement of Clopidogrel is 
rational. Because there is limited 
advantages of using Clopidogrel over 
aspirin in the antiplatelet medication as 
proven by the CAPRIE trial, and the cost-
effectiveness still confirms that using 
aspirin is more cost effective than 
Clopidogrel. Moreover, through the safety 
and effectiveness study performed in 
MATCH trial shows that combination of 
aspirin and Clopidogrel yielded a 
significant life threatening bleeding 
compared to monotherapy of Clopidogrel. 
In the MATCH trial showed also that 
effectiveness of combination aspirin and 
Clopidogrel compared to Clopidogrel is 
nonsignificant in reducing relative risk of 
the primary endpoint. 
7. Which disease is targeted by the drug? 
Clopidogrel is an antagonis of ADP 
receptor. The drug is targeted for the 
reduction of atheroschlerotic events 
including myocardial infarction, stroke, or 
peripheral artery disease, and is used in 
patients with non –ST segment elevation. 
8. What is the impact of the drug compared to 
other drug? 
In the area of antiplatelet therapy, aspirin 
remains the first line of therapy. Only for 
patient who shows intolerance to aspirin, 
Clopidogrel will be the given. Combination 
of aspirin and Clopidogrel is in the second 
line of therapy.  
9 What is the information that still lacking? 
The effectiveness study in CAPRIE trial 
challenges the conflicting interpretation 
from other investigators about the 
superiority of Clopidogrel to aspirin. 
Heterogenicity between subgroup in 
CAPRIE trial is thought to be favorable for 
the interpretation of the advantage therapy 
of Clopidogrel over aspirin (Garattini & 
Bertele, 2004). Moreover, comparison 
study in meta-analysis between Clopidogrel 
and ticlopidine results in different 
interpretation. For 30 days therapy, 
Clopidogrel showed the significant benefit 
over ticlopidine in reducing mortality, 
however another investigator with longer 
investigation on Clopidogrel therapy (28 
weeks) compared to ticlopidine showed 
that mortality is significantly higher in 
Clopidogrel treated group.   Therefore, up 
to my understanding, the information that is 
still lacking is that the true conclusion 
whether Clopidogrel is only slightly 
advantage over aspirin or Clopidogrel 
provides a big significant benefit over 
aspirin and also ticlopidine. It might be 
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useful to design the comparison of 
Clopidogrel and aspirin with avoiding such 
heterogenicity. Moreover, comparison 
study in Clopidogrel and ticlopidine is 
might be necessary in term of longer time 
of therapy.    
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